Trade Adverum Biotechn - ADVM CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0460 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.312 |
Open | 3.352 |
1-Year Change | -65.78% |
Day's Range | 3.352 - 3.552 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 2, 2025 | 3.4620 | 0.1200 | 3.59% | 3.3420 | 3.5720 | 3.3420 |
May 1, 2025 | 3.3120 | 0.1300 | 4.09% | 3.1820 | 3.3720 | 3.1020 |
Apr 30, 2025 | 3.2420 | 0.1300 | 4.18% | 3.1120 | 3.3120 | 3.0520 |
Apr 29, 2025 | 3.1920 | 0.3600 | 12.71% | 2.8320 | 3.2420 | 2.7720 |
Apr 28, 2025 | 2.8620 | -0.0300 | -1.04% | 2.8920 | 2.9220 | 2.6220 |
Apr 25, 2025 | 2.9020 | 0.0100 | 0.35% | 2.8920 | 2.9820 | 2.7820 |
Apr 24, 2025 | 2.9520 | 0.1300 | 4.61% | 2.8220 | 3.0720 | 2.8220 |
Apr 23, 2025 | 2.8320 | -0.1300 | -4.39% | 2.9620 | 2.9720 | 2.7820 |
Apr 22, 2025 | 2.9420 | 0.2100 | 7.69% | 2.7320 | 3.0020 | 2.7220 |
Apr 21, 2025 | 2.7120 | -0.1700 | -5.90% | 2.8820 | 2.9920 | 2.6920 |
Apr 17, 2025 | 2.9020 | -0.1100 | -3.65% | 3.0120 | 3.0120 | 2.7220 |
Apr 16, 2025 | 2.9620 | -0.1400 | -4.51% | 3.1020 | 3.2220 | 2.8620 |
Apr 15, 2025 | 3.1820 | -0.1000 | -3.05% | 3.2820 | 3.6120 | 3.0720 |
Apr 14, 2025 | 3.4120 | 0.0800 | 2.40% | 3.3320 | 3.5220 | 3.2220 |
Apr 11, 2025 | 3.3820 | 0.1800 | 5.62% | 3.2020 | 3.4520 | 3.2020 |
Apr 10, 2025 | 3.3020 | -0.2100 | -5.98% | 3.5120 | 3.5120 | 3.1720 |
Apr 9, 2025 | 3.5620 | 0.2600 | 7.87% | 3.3020 | 3.6520 | 3.0420 |
Apr 8, 2025 | 3.3820 | -0.2400 | -6.63% | 3.6220 | 3.7520 | 3.2920 |
Apr 7, 2025 | 3.5920 | -0.1000 | -2.71% | 3.6920 | 3.8520 | 3.3820 |
Apr 4, 2025 | 3.8320 | 0.0700 | 1.86% | 3.7620 | 3.9920 | 3.7320 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Adverum Biotechn Company profile
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adverum Biotechnologies Inc revenues increased from $0K to $7.5M. Net loss increased 39% to $111.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 74% to $37.8M (expense), Research and development -gross increase of 31% to $59.5M (expense).
Industry: | Bio Therapeutic Drugs |
100 Cardinal Way
REDWOOD CITY
CALIFORNIA 94063
US
News

GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com